Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmo Bio CoTSE:3386 +3.63%73 ROC (Joel Greenblatt) % is 6.95% as of Dec. 2025, which is 49% below its 10-year median of 13.76. GuruFocus rates TSE:3386 with a GF Score™ of 73/100 and a GF Value™ of 円1,249.78 (Fairly Valued). The stock has 4 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Cosmo Bio Co ranks better than 63.81% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Cosmo Bio Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 6.95%.
The historical rank and industry rank for Cosmo Bio Co's ROC (Joel Greenblatt) % or its related term are showing as below:
TSE:3386'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 9.42 Med: 13.76 Max: 34.37
Current: 12.77
During the past 13 years, Cosmo Bio Co's highest ROC (Joel Greenblatt) % was 34.37%. The lowest was 9.42%. And the median was 13.76%.
TSE:3386's ROC (Joel Greenblatt) % is ranked better than 63.81% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.815
vs TSE:3386: 12.77
Cosmo Bio Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -22.60% per year.
Cosmo Bio Co (TSE:3386) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Cosmo Bio Co ROC (Joel Greenblatt) % Related Terms
Cosmo Bio Co ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Cosmo Bio Co's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3386 vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, Cosmo Bio Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Bio Co ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cosmo Bio Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Cosmo Bio Co's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 6.95% mean?
Cosmo Bio Co (TSE:3386) has a ROC (Joel Greenblatt) % of 6.95% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cosmo Bio Co and its competitors. This is 49% below median its historical median of 13.76. Over the past decade, Cosmo Bio Co's ROC (Joel Greenblatt) % has ranged from 9.42 to 34.37. According to the industry distribution chart, Cosmo Bio Co ranks #76 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 36.2%.
Is Cosmo Bio Co's ROC (Joel Greenblatt) % too high?
Cosmo Bio Co's current ROC (Joel Greenblatt) % of 6.95% is 49% below median its 10-year median of 13.76. Over the past 10 years, this metric has ranged from a low of 9.42 to a high of 34.37. Based on the distribution chart, Cosmo Bio Co ranks #76 out of 210 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Cosmo Bio Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosmo Bio Co's ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cosmo Bio Co ranks #76 out of 210 companies for ROC (Joel Greenblatt) %. This puts Cosmo Bio Co in the upper half of its industry. Historically, Cosmo Bio Co's own ROC (Joel Greenblatt) % has ranged from 9.42 to 34.37 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cosmo Bio Co and its competitors. Cosmo Bio Co's current ROC (Joel Greenblatt) % is 6.95%, which is 49% below median its own 10-year median of 13.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo Bio Co stock overvalued right now?
Based on GuruFocus' analysis, Cosmo Bio Co (TSE:3386) is currently considered Fairly Valued. The stock's GF Value™ is 円1,249.78, compared to a current price of 円1,285.00 — trading 2.8% above its estimated fair value. The current ROC (Joel Greenblatt) % is 6.95%, which is 49% below median its 10-year median of 13.76. Cosmo Bio Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Cosmo Bio Co (TSE:3386), the current ROC (Joel Greenblatt) % is 6.95% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo Bio Co (TSE:3386) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo Bio Co stock appears to be overvalued.
The current stock price of 円1,285.00 is trading 2.8% above its estimated GF Value™ of 円1,249.78.
GuruFocus considers Cosmo Bio Co to be Fairly Valued.
Key valuation signals for TSE:3386:
ROC (Joel Greenblatt) %: 6.95% (49% below median its 10-year median of 13.76)
GF Value™: 円1,249.78 vs. price of 円1,285.00 (2.8% above fair value)
No single metric tells the full story. See the TSE:3386 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo Bio Co Ltd is a diagnostic and research company based in Japan. The business of the company includes the purchase of reagents, instruments, and clinical test drugs for research in life science and domestic sales.
73GF Score
Get the complete analysis for TSE:3386
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3386 has been successfully added to your 
